Memorial Sloan Kettering surgeon Danielle Bello

Danielle Bello, MD

Surgical Oncologist

Titles

Assistant Attending Surgeon

Clinical Expertise

Melanoma; Merkel Cell Carcinoma; Squamous Cell Carcinoma; Basal Cell Carcinomas; Sweat Gland Tumors

Share

New Patient Appointments

Scheduling a visit is easy. Click below or call us to get started.

Monday through Friday, 8:00 a.m. to 6:00 p.m., (Eastern time)
Accepted Insurance Providers

Dr. Bello accepts the following list of insurance providers. Select your insurance provider to see more details.

Aetna

Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS, Transplant

Aetna Medicare Advantage (City of NY retirees only, starting 7/1/23)

Payor Type:
In Network Coverage Type(s): PPO

Blue Cross Blue Shield Federal Employee Program

Payor Type: Commercial
In Network Coverage Type(s): HMO, PPO

Blue Cross Blue Shield New York

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO

Blue Cross Blue Shield states outside of NY/NJ

Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS

Blue Cross Health Plus

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Carrum Health

Payor Type: Commercial
In Network Coverage Type(s): Supplemental

Cigna

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO

Connecticare

Payor Type: Commercial
In Network Coverage Type(s): POS, EPO, HMO

Emblem

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO

Emblem Essential

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Emblem Medicare Advantage

Payor Type:
In Network Coverage Type(s): PPO, HMO

Empire Blue Cross Medicare Advantage

Payor Type:
In Network Coverage Type(s): PPO, HMO, DSN

Empire Essential

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Empire Plan / NYSHIP (Blue Cross/UnitedHealthcare split plan)

Payor Type: Commercial
In Network Coverage Type(s): PPO

Fidelis

Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO

Fidelis Managed Medicaid & HARP

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Fidelis Medicare Advantage

Payor Type:
In Network Coverage Type(s): HMO

First Health

Payor Type:
In Network Coverage Type(s): PPO

Healthfirst

Payor Type: Commercial
In Network Coverage Type(s): EPO, HMO, PPO, POS

Healthfirst Managed Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Healthfirst Medicare Advantage

Payor Type:
In Network Coverage Type(s): HMO, PPO

Healthsmart

Payor Type: Commercial
In Network Coverage Type(s): PPO EPO

Horizon Blue Cross Blue Shield New Jersey (HMO)

Payor Type: Commercial
In Network Coverage Type(s): HMO

Horizon Blue Cross Blue Shield New Jersey (PPO)

Payor Type: Commercial
In Network Coverage Type(s): PPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier I (EPO)

Payor Type: Commercial
In Network Coverage Type(s): EPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier II (EPO)

Payor Type: Commercial
In Network Coverage Type(s): EPO

Horizon Medicare Advantage

Payor Type:
In Network Coverage Type(s): PPO, HMO

Husky CT Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government

Magnacare

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO

Medicare Part A&B (traditional Medicare)

Payor Type:
In Network Coverage Type(s): Federal Government

Multiplan/Beech Street/PHCS

Payor Type: Commercial
In Network Coverage Type(s): Supplemental

MVP

Payor Type: Commercial
In Network Coverage Type(s): PPO/OAP

Non-Participating Plans with Out of Network Benefits

Payor Type: Other
In Network Coverage Type(s): PPO, POS, EPO, HMO

NYC Medicare Advantage Plus for City Employees

Payor Type:
In Network Coverage Type(s): TBD

Oscar

Payor Type: Commercial
In Network Coverage Type(s): HMO/EPO

Oxford

Payor Type: Commercial
In Network Coverage Type(s): PPO, EPO

Qualcare

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO

Straight NJ Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government

Straight NY Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government

Tricare

Payor Type: Commercial
In Network Coverage Type(s): PPO, HMO

UMR

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS

United Healthcare

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO

World Trade Center Health Program (WTC)

Payor Type: Commercial
In Network Coverage Type(s): State Government

Contact and Location

Locations map
Find a Convenient Location

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.

See all locations

About Me

Education

MD, Mount Sinai School of Medicine

Residencies

Surgery – Yale University School of Medicine

Fellowships

Surgical Oncology – Memorial Sloan Kettering Cancer Center

Board Certifications

General Surgery, Surgical Oncology

I am a surgical oncologist specializing in the care of patients with cutaneous malignancies, including melanoma, Merkel cell carcinoma, squamous cell carcinoma, basal cell carcinoma, and sweat gland tumors. From my practice in MSK Commack (Long Island, New York) and MSK Monmouth (Middletown, New Jersey), I see anywhere from 800 to 1,000 patients with cutaneous malignancies each year.

Read more

When patients come to me, they are often concerned about what their diagnosis means for their well-being and quality of life. I understand that a cancer diagnosis can be unnerving, and I take the time to answer patients’ questions about their disease patiently and empathetically. At Memorial Sloan Kettering Cancer Center, I work closely with colleagues across medical oncology, radiation oncology, pathology, nursing, and supportive care, who all specialize in the treatment of cutaneous malignancies. We spend time with our patients and their loved ones to understand their unique needs and wishes and ultimately, to recommend a treatment plan that is best for them.

I decided to pursue a career in oncology because I felt that this field was where I could make a difference. Most people will be affected by cancer at some point in their lives, either personally or through connection to a loved one, and this can take both a physical and an emotional toll. I wanted to be a part of their solution—not just by surgically treating their disease, but also by supporting them in their journey and individualizing their care so they get the best possible treatment for them. It is important to me that patients and their caregivers know that they are receiving personalized, state-of-the-art care and feel uplifted by our team of experts at each step in the process.

In addition to providing compassionate care to all who come to me, I am committed to bettering outcomes for patients with cutaneous malignancies through the study of different subsets of melanoma, such as acral melanoma. The less common types of melanomas are genetically distinct from the more common cutaneous melanomas. By better understanding these differences, I believe that we can improve how we care for people with these diseases.

Beyond researching these subsets, I am also investigating new ways to combine surgery with immunotherapy to boost outcomes in patients with advanced or metastatic melanoma. I am currently involved in investigative efforts aimed at defining the role of intralesional therapies for patients with in-transit metastases to improve outcomes in this group of patients.

Awards and Honors

  • David and Monica Gorin Award of Courage Fellow, Memorial Sloan Kettering Cancer Center (2017-2018)

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Gastric and Mixed Tumor Service doctors

Clinical Trials

Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

Kurtansky NR, Manci RN, Bello DM, Adamson AS, Shoushtari AN, Wehner MR, Ariyan CE, Marghoob AA, Marchetti MA, Rotemberg V. Risk of nonacral cutaneous melanoma after the diagnosis of acral melanoma. Br J Dermatol. 2022 Mar 23. doi: 10.1111/bjd.21251. Online ahead of print. PMID: 35318644 No abstract available.

Thomas D, Bello DM. Adjuvant immunotherapy for melanoma. J Surg Oncol. 2021 Mar;123(3):789-797.

Sahu, A, Oh, Y, Peterson G. Cordova M, Navarrete-Dechent C, Gill M, Alessi-Fox C, Gonzalez S, Phillips W, Wilson S, Afzalneia R, Rose R, Mohsen A, Bello D, Marghoob A, Rossi A, Wolchok JD, Merghoub T, Rotemberg V, Chen CSJ, Rajadhyaksha M In vivo optical imaging-guided targeted sampling for precise diagnosis and molecular pathology. Sci Rep. 2021 Nov 30;11(1):23124.

Bello DM, Faries MB. The Landmark Series: MSLT-1, MSLT-2 and DeCOG (Management of Lymph Nodes). Ann Surg Oncol. 2020 Jan;27(1):15-21.

Bello DM, Ariyan CE. ASO Author Reflections: Is There a Re-invigorated Role for Melanoma Metastasectomy in a Checkpoint Blockade Era? Ann Surg Oncol. 2020 Jan 17.

Bello DM. Indications for the surgical resection of stage IV disease. J Surg Oncol. 2019

Bello DM, Panageas KS, Hollmann TJ, Shoushtari AN, Chapman P, Postow MA, Callahan MK, Wolchok JD, Brady MS, Coit D, Ariyan CE. Outcomes of Patients with Metastatic Melanoma Selected for Surgery After Immunotherapy. Plenary presentation at the 71st Annual Meeting of the Society of Surgical Oncology, March 21-24, 2018, Chicago, IL.

Bello DM, Ariyan CE. Adjuvant Therapy in the Treatment of Melanoma. Ann Surg Oncol. 2018 Jul;25(7):1807-1813.

Bello DM, Panageas KS, Hollmann T, Shoushtari AN, Momtaz P, Chapman PB, Postow MA, Callahan MK, Wolchok JD, Brady MS, Coit DG, Ariyan CE. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. Ann Surg Oncol. 2019 Dec 17.

Bello DM, Han G, Jackson L, Bulloch K, Ariyan S, Narayan D, Rothberg BG, Han D. The Prognostic Significance of Sentinel Lymph Node Status for Patients with Thick Melanoma. Ann Surg Oncol. 2016 Dec;23(Suppl 5):938-945.

Bello DM, Chou JF, Panageas KS, Brady MS, Coit DG, Carvajal RD, Ariyan CE. Prognosis of acral melanoma: a series of 281 patients. Ann Surg Oncol. 2013 Oct;20(11):3618-25.

Publications on PubMed

Visit PubMed for a full listing of Dr. Bello’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Danielle Bello discloses the following relationships and financial interests:

  • Philogen S.p.A.
    Provision of Services (uncompensated)

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures